NZ723838A - Cannabinoid compositions and uses - Google Patents

Cannabinoid compositions and uses

Info

Publication number
NZ723838A
NZ723838A NZ723838A NZ72383815A NZ723838A NZ 723838 A NZ723838 A NZ 723838A NZ 723838 A NZ723838 A NZ 723838A NZ 72383815 A NZ72383815 A NZ 72383815A NZ 723838 A NZ723838 A NZ 723838A
Authority
NZ
New Zealand
Prior art keywords
glycol
composition
monohydric
polyhydric alcohol
cannabinoid compositions
Prior art date
Application number
NZ723838A
Other languages
English (en)
Inventor
Alex Hearn
Ritika Gupta
Moira Bowdrey
Original Assignee
Kind Consumer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kind Consumer Ltd filed Critical Kind Consumer Ltd
Priority to NZ754337A priority Critical patent/NZ754337B2/en
Publication of NZ723838A publication Critical patent/NZ723838A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/20—Devices using solid inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/60—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0093—Inhalators mechanically breath-triggered without arming or cocking, e.g. acting directly on the delivery valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
NZ723838A 2014-02-14 2015-02-13 Cannabinoid compositions and uses NZ723838A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ754337A NZ754337B2 (en) 2014-02-14 2015-02-13 A cannabinoid inhaler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1402678.5A GB2524469A (en) 2014-02-14 2014-02-14 A cannabinoid inhaler and composition therefor
US201461941724P 2014-02-19 2014-02-19
GB1420943.1A GB2525269A (en) 2014-02-14 2014-11-25 Cannabinoid compositions and uses
PCT/GB2015/050418 WO2015121673A1 (fr) 2014-02-14 2015-02-13 Compositions de cannabinoïdes et utilisations

Publications (1)

Publication Number Publication Date
NZ723838A true NZ723838A (en) 2019-08-30

Family

ID=50440210

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ723838A NZ723838A (en) 2014-02-14 2015-02-13 Cannabinoid compositions and uses

Country Status (10)

Country Link
US (4) US10413521B2 (fr)
EP (1) EP3104837A1 (fr)
JP (2) JP6391701B2 (fr)
AU (1) AU2015216718B2 (fr)
CA (2) CA2939242C (fr)
GB (2) GB2524469A (fr)
IL (1) IL247262B (fr)
MX (1) MX2016010541A (fr)
NZ (1) NZ723838A (fr)
WO (1) WO2015121673A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
JP6676062B2 (ja) * 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
RU2720169C2 (ru) 2015-07-20 2020-04-24 Медикал Дивелопментс Интернэшнл Лимитед Ингаляторное устройство для ингаляционных жидкостей
GB2542389A (en) * 2015-09-17 2017-03-22 Kind Consumer Ltd Simulated cigarette
CN205196999U (zh) * 2015-11-23 2016-05-04 深圳市合元科技有限公司 雾化器及电子烟
CA2995970A1 (fr) * 2017-02-22 2018-08-22 Gene Bernaudo Systeme de composition d'agent de melange destine aux cigarettes electroniques
GB201712159D0 (en) * 2017-07-28 2017-09-13 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2567240B (en) * 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
US20200330378A1 (en) * 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
US20220142970A1 (en) * 2019-03-24 2022-05-12 Buzzelet Development And Technologies Ltd. Cannabis inhalation products and methods of production thereof
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
GB2588087A (en) * 2019-09-27 2021-04-21 Senzer Ltd Inhalable cannabinoid compositions and uses
GB2595692A (en) 2020-06-03 2021-12-08 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
US20220015443A1 (en) * 2020-07-15 2022-01-20 Altria Client Services Llc Steady state resistance estimation for overheating protection of a non-nicotine e-vaping device
US11744285B2 (en) 2020-07-15 2023-09-05 Altria Client Services Llc Steady state resistance estimation for overheating protection of a nicotine e-vaping device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
ES2246883T3 (es) * 1999-08-20 2006-03-01 Unimed Pharmaceuticals Inc. Composicion para inhalacion que comprende delt-9-tetrahidrocanabidol en un disolvente semiacuoso.
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
DK1280515T3 (da) * 2000-03-09 2007-06-11 Gw Pharma Ltd Farmaceutiske sammensætninger omfattende cannabis
GB2361869B (en) 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
EP1321159A1 (fr) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
US20080159961A1 (en) 2002-06-22 2008-07-03 Austen John Woolfe Pharmaceutical Composition
CN101203208A (zh) 2005-06-20 2008-06-18 尤尼麦德制药公司 屈大麻酚治疗偏头痛
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
EP2207528B1 (fr) * 2007-10-05 2013-10-09 STI Pharmaceuticals Ltd. Composition pharmaceutique
GB0823491D0 (en) * 2008-12-23 2009-01-28 Kind Consumer Ltd A simulated cigarette device
RU2529693C2 (ru) 2009-08-07 2014-09-27 Кайнд Консьюмер Лимитед Ингалятор
GB201003552D0 (en) 2010-03-03 2010-04-21 Kind Consumer Ltd A simulated cigarette
GB201004861D0 (en) * 2010-03-23 2010-05-05 Kind Consumer Ltd A simulated cigarette
WO2012021291A2 (fr) 2010-08-09 2012-02-16 University Of Maryland, Baltimore Procédés de traitement des troubles pulmonaires obstructifs en utilisant des substances sapides amères
CN104582772B (zh) * 2012-07-05 2018-02-09 葛兰素集团有限公司 吸入器装置
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
CA2883135C (fr) * 2012-08-28 2018-03-20 Kind Consumer Limited Inhalateur simulant la force d'aspiration d'une cigarette
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof

Also Published As

Publication number Publication date
JP2018150334A (ja) 2018-09-27
IL247262B (en) 2020-07-30
US10561634B2 (en) 2020-02-18
AU2015216718B2 (en) 2017-11-16
JP6391701B2 (ja) 2018-09-19
EP3104837A1 (fr) 2016-12-21
GB201402678D0 (en) 2014-04-02
AU2015216718A1 (en) 2016-09-01
CA2939242A1 (fr) 2015-08-20
WO2015121673A1 (fr) 2015-08-20
CA3014697A1 (fr) 2015-08-20
US10413521B2 (en) 2019-09-17
MX2016010541A (es) 2016-11-29
GB2524469A (en) 2015-09-30
GB201420943D0 (en) 2015-01-07
IL247262A0 (en) 2016-09-29
US20200163932A1 (en) 2020-05-28
CA2939242C (fr) 2018-12-18
JP2017506639A (ja) 2017-03-09
US20170056368A1 (en) 2017-03-02
GB2525269A (en) 2015-10-21
US20190358195A1 (en) 2019-11-28
CA3014697C (fr) 2021-05-04
US20200147035A1 (en) 2020-05-14
NZ754337A (en) 2021-10-29

Similar Documents

Publication Publication Date Title
NZ723838A (en) Cannabinoid compositions and uses
PH12015500686A1 (en) Nicotine composition
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021006035A (es) Formulaciones cannabinoides estables.
MX2023007033A (es) Extractos de cannabis y metodos de preparacion y uso de la misma.
MX2019001286A (es) Composicion de cannabis.
TN2016000007A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
WO2015033302A3 (fr) Compositions de fulvestrant
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
MX362905B (es) Tratamiento de combinacion.
IN2013MU01177A (fr)
MX2019011701A (es) Composiciones de canabinoide y usos.
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds
WO2014106826A3 (fr) Analogue d'anthracycline et utilisations associées
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20200117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2022 BY CAMILLA WELLIN

Effective date: 20210129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20220210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2025 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20240201